Retatrutide is a new treatment in the fight against obesity. This groundbreaking drug, belonging to a dual GLP-1 and GIP receptor agonist, shows promising results in clinical trials. By activating these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately results in significant reduction in body mass. While studies